LT3652145T - Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas - Google Patents

Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas

Info

Publication number
LT3652145T
LT3652145T LTEPPCT/EP2019/061441T LTEP2019061441T LT3652145T LT 3652145 T LT3652145 T LT 3652145T LT EP2019061441 T LTEP2019061441 T LT EP2019061441T LT 3652145 T LT3652145 T LT 3652145T
Authority
LT
Lithuania
Prior art keywords
crystalline form
pharmaceutical use
triethylenetetramine tetrahydrochloride
tetrahydrochloride
triethylenetetramine
Prior art date
Application number
LTEPPCT/EP2019/061441T
Other languages
English (en)
Inventor
Timothy James Morley
Ronnie Maxwell Lawrence
Naseem AMIN
Original Assignee
Orphalan S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62455418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3652145(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orphalan S.A. filed Critical Orphalan S.A.
Publication of LT3652145T publication Critical patent/LT3652145T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/84Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/EP2019/061441T 2018-05-04 2019-05-03 Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas LT3652145T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18290048 2018-05-04
PCT/EP2019/061441 WO2019211464A1 (en) 2018-05-04 2019-05-03 Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Publications (1)

Publication Number Publication Date
LT3652145T true LT3652145T (lt) 2026-01-26

Family

ID=62455418

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2019/061441T LT3652145T (lt) 2018-05-04 2019-05-03 Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas

Country Status (26)

Country Link
US (7) US10988436B2 (lt)
EP (2) EP3652145B1 (lt)
JP (2) JP7679294B2 (lt)
KR (2) KR20250121158A (lt)
CN (3) CN114394904A (lt)
AR (1) AR115080A1 (lt)
AU (2) AU2019263969B2 (lt)
CA (1) CA3096423A1 (lt)
CO (1) CO2020013806A2 (lt)
DE (1) DE19724752T1 (lt)
DK (1) DK3652145T3 (lt)
EA (1) EA202092241A1 (lt)
ES (1) ES2769049T3 (lt)
FI (1) FI3652145T3 (lt)
HR (1) HRP20251307T1 (lt)
LT (1) LT3652145T (lt)
MA (2) MA58726B1 (lt)
PL (1) PL3652145T3 (lt)
PT (1) PT3652145T (lt)
RS (1) RS67287B1 (lt)
SA (1) SA520420467B1 (lt)
SG (1) SG11202010785UA (lt)
SI (1) SI3652145T1 (lt)
SM (1) SMT202500387T1 (lt)
TW (1) TWI902661B (lt)
WO (1) WO2019211464A1 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3652145T (lt) * 2018-05-04 2026-01-26 Orphalan S.A. Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas
KR102489293B1 (ko) * 2020-10-15 2023-01-17 (주) 에프엔지리서치 공업용 등급의 트리에틸렌테트라민의 고순도 정제 방법
AR125456A1 (es) 2021-04-26 2023-07-19 Orphalan S A Control de la concentración de cobre no ligado a la ceruloplasmina
TWI819502B (zh) * 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
CN116675607A (zh) * 2022-02-23 2023-09-01 裕捷股份有限公司 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
EP4558486A1 (en) * 2022-07-19 2025-05-28 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form a of n, n'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride
EP4487839A1 (en) 2023-07-03 2025-01-08 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical dosage form comprising trientine tetrahydrochloride, and method for preparing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
CS197093B1 (cs) * 1978-06-16 1980-04-30 Ivo Kuhr Způsob přípravy čistého dihydrochloridu triethylentetraminu
DE19724752A1 (de) 1997-04-24 1998-11-05 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut
MXPA00009705A (es) 1998-04-03 2003-07-14 Univ Manitoba Uso de poliaminas en el tratamiento de sintomas dermatologicos.
JP4369003B2 (ja) 2000-02-23 2009-11-18 ハリマ化成株式会社 ハンダ付け用フラックス
WO2003077901A1 (en) 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
AU2003214725A1 (en) 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
NZ545724A (en) 2003-03-18 2007-11-30 Protemix Corp Ltd Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
CA2577634C (en) 2004-07-19 2015-07-07 Protemix Corporation Limited Synthesis of triethylenetetramines
CN106278907B (zh) * 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
JP6326477B2 (ja) 2015-12-25 2018-05-16 三洋化成工業株式会社 高分子凝集剤
LT3652145T (lt) 2018-05-04 2026-01-26 Orphalan S.A. Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas
WO2020006027A1 (en) 2018-06-29 2020-01-02 Sharp Laboratories Of America, Inc. Ultra-reliability design for physical uplink control channel (pucch) in 5th generation (5g) new radio (nr)
CN109076617B (zh) 2018-07-25 2022-08-19 北京小米移动软件有限公司 Mtc系统的随机接入方法、装置及存储介质
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物

Also Published As

Publication number Publication date
EP4613337A3 (en) 2025-09-17
NZ768613A (en) 2025-06-27
DE19724752T1 (de) 2020-07-09
US20250074862A1 (en) 2025-03-06
WO2019211464A1 (en) 2019-11-07
PT3652145T (pt) 2025-09-29
BR112020018451A2 (pt) 2020-12-29
US12358862B2 (en) 2025-07-15
CA3096423A1 (en) 2019-11-07
PL3652145T3 (pl) 2025-12-22
CN111479798B (zh) 2024-11-01
AU2019263969A1 (en) 2020-10-22
US20200392068A1 (en) 2020-12-17
KR102843554B1 (ko) 2025-08-08
DK3652145T3 (da) 2025-10-20
EP3652145B1 (en) 2025-09-17
CN114394904A (zh) 2022-04-26
ES2769049T3 (en) 2025-11-21
SMT202500387T1 (it) 2025-11-10
US10988436B2 (en) 2021-04-27
AU2019263969B2 (en) 2024-08-01
SG11202010785UA (en) 2020-11-27
JP2025037978A (ja) 2025-03-18
US20210188761A1 (en) 2021-06-24
KR20250121158A (ko) 2025-08-11
TWI902661B (zh) 2025-11-01
JP2021531322A (ja) 2021-11-18
CN111479798A (zh) 2020-07-31
TW202002956A (zh) 2020-01-16
US20240360071A1 (en) 2024-10-31
HRP20251307T1 (hr) 2025-12-05
US20250382257A1 (en) 2025-12-18
US11072577B2 (en) 2021-07-27
MA58726B1 (fr) 2025-02-28
SA520420467B1 (ar) 2024-04-28
FI3652145T3 (fi) 2025-10-22
US20220169594A1 (en) 2022-06-02
US12358861B2 (en) 2025-07-15
EP4613337A2 (en) 2025-09-10
JP7679294B2 (ja) 2025-05-19
AR115080A1 (es) 2020-11-25
CN119306616A (zh) 2025-01-14
ES2769049T1 (es) 2020-06-24
MA58726A1 (fr) 2023-09-27
EA202092241A1 (ru) 2021-04-01
KR20210005270A (ko) 2021-01-13
EP3652145A1 (en) 2020-05-20
US11117855B2 (en) 2021-09-14
CO2020013806A2 (es) 2021-01-29
AU2024227767A1 (en) 2024-11-21
SI3652145T1 (sl) 2025-12-31
US20210163398A1 (en) 2021-06-03
RS67287B1 (sr) 2025-11-28
MA51919A1 (fr) 2021-11-30

Similar Documents

Publication Publication Date Title
LT3652145T (lt) Trietilentetramino tetrahidrochlorido kristalinė forma ir jos farmacinis naudojimas
NL301322I2 (nl) Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
IL254207B (en) Oral care compositions and methods of use
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
EP3604311A4 (en) PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND
IL290745A (en) A pyrimidine compound and its pharmaceutical use
EP3465539A4 (en) DETECTION OF INTERNAL TUMOR AND SYNCHRONIZED SURFACE
LT3368571T (lt) Į transformuojantį augimo faktorių beta atsaką sukuriantys polipeptidai ir jų panaudojimo būdai
HUE059605T2 (hu) TLR agonista tartalmú készítmény és használati eljárások
FI20140067L (fi) Nanoselluloosan ja sen esiasteiden valmistus ja käyttö
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
IL281892A (en) Amorphous form of chelating agents and process for preparing them
IL284218A (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
HUE043194T2 (hu) PLK-4 inhibitor sója és kristályformái
LT3573611T (lt) Amidų junginiai ir jų naudojimas
LT3512495T (lt) Prostaciklino analogo vaisto formos
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
IL282157A (en) Compounds and therapeutic uses thereof
LT3423042T (lt) Liofilizuota farmacinė vaisto forma ir jos panaudojimas
BR112016017087A2 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
IL246428A0 (en) Synthetic co-crystals of anhydrous guanine and process for preparing the same
DE102015122373A8 (de) Lagerungskissen zur Lagerung des Unterarmes
LT3601277T (lt) Farmacinė vaisto forma
LT3867244T (lt) 4-pirazin-2-ilmetil-morfolino dariniai ir jų naudojimas kaip vaisto